SBIR/STTR Research Award
TEICHOS LABORATORIES, LLC. ""AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT"".
Award amount
$300,000Program and phase
SBIR · Phase IAward year
2023Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- TEICHOS LABORATORIES, LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- UGFLPLUM9UP5
- Solicitation number
- PHS-2023-1
- Topic code
- 117
Research abstract
The project will optimize a novel adjuvant formulation composed of alum and TL-001, a unique totally synthetic peptidoglycan (sPGN) TLR2 agonist, to improve performance of a registered DTaP subunit vaccine. Preliminary results with TL-001 strongly suggest potential as a non-toxic, single agent vaccine adjuvant. TL-001 and a phosphonylated analogue (pTL-001) will be prepared and their respective affinities for aluminum hydroxide adjuvant (AH) will be compared. Proof-of-concept studies will determine if pTL-001, the novel, soluble, immune response amplifier, combined with alum, enhances the magnitude and quality of humoral and cellular responses compared to the registered vaccine. The project will scale production of TL-001 and pTL-001 for characterization of dose-related induction.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Immunotherapy for Factor VIII Inhibition in Hemophilia A
- A Totally Synthetic Immunostimulator that Targets Toll-like Receptor 2 and NOD2: Toward Improved Influenza Vaccines
- AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH ANOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- TENDEL THERAPIES, INC. (75N93023C00030) TITLE: TFH-TARGETING GENETIC ADJUVANTS TO PROMOTE DURABLE ANTI-INFLUENZA STEM ANTIBODIES IN OLDER ADULTS.
- POP TECHNOLOGIES, INC., ""MULTIVALENT QS-18 PROTEIN NANOPARTICLES FOR A BROADLY PROTECTIVE INFLUENZA VIRUS VACCINE"".
Research funding history
4 SBIR/STTR records share this UEI (2021–2023). Reported award amounts total $1,102,613. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services